Drug Profile

EG 101

Alternative Names: EG-101; EG-ZNMP-01

Latest Information Update: 20 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Evergreen Therapeutics
Class Antihypertensives; Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Preeclampsia
New Molecular Entity Yes

Highest Development Phases

Preclinical Preeclampsia

Most Recent Events

12 Jan 2026 Evergreen Therapeutics plans a phase-I trial for Preeclampsia (In volunteers) in June 2026 (IV, Injection) (NCT07327255)
30 Apr 2025 US FDA approves IND application for EG 101 in Preeclampsia
10 Oct 2024 Preclinical trials in Preeclampsia in USA (unspecified route) prior to October 2024 (Evergreen Therapeutics pipeline, October 2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com